John Vandermosten

Anita Dushyanth

- **Titan Pharmaceuticals, Inc. (TTNP)** completed its previously announced business combination on **October 1, 2025**, resulting in TTNP becoming a direct wholly owned subsidiary of **Black Titan Corporation**.  **[910267_0001829126-25-007823_titanpharma_8k.htm:0]** 
- As a consequence of the merger, TTNP common stock is anticipated to **cease trading on the Nasdaq Capital Market**, and **Black Titan Corporation's Ordinary Shares** are expected to begin trading on Nasdaq commencing **October 2, 2025**.  **[910267_0001829126-25-007823_titanpharma_8k.htm:1]** 
- Effective **October 1, 2025**, TTNP's directors and officers resigned, and **Chay Weei Jye** was appointed as the sole director and acting secretary of TTNP.  **[910267_0001829126-25-007823_titanpharma_8k.htm:3]** **[910267_0001829126-25-007823_titanpharma_8k.htm:4]** 
- Stockholders of TTNP immediately prior to the merger ceased to have any rights as stockholders of TTNP, other than the right to receive the Stockholder Consideration.  **[910267_0001829126-25-007823_titanpharma_8k.htm:1]**

TITAN PHARMACEUTICALS (TTNP)